Results 201 to 210 of about 36,390 (302)

Early and Sustained Asthma Control and Remission in Real-World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC-2. [PDF]

Clin Exp Allergy
Penz E, Rothe T, Dupont L, Tran TN, Menzies-Gow A, Shavit A, Cohen D, Plate T, Kayaniyil S, Herreman A, Schuoler C, Emmanuel B, Lommatzsch M.   +12 more
europepmc   +1 more source

Asthma and Multimorbidity Amongst Ethnic Minority Groups in High Income Countries

Clinical &Experimental Allergy, EarlyView.
There is a tight intersection between asthma, deprivation, ethnicity, multimorbidity and poor clinical outcomes. An integrated, holistic and culturally tailored approach is needed to improve clinical outcomes amongst ethnic minority groups with asthma and multimorbidity. ABSTRACT Asthma is one of the commonest noncommunicable diseases worldwide.
Mamidipudi Thirumala Krishna, Saibal Moitra, Anna Freeman, Ben Ainsworth, Rebecca Knibb, Ramesh Kurukulaaratchy, Adel H. Mansur   +6 more
wiley   +1 more source

Efficacy of Benralizumab in Reducing FeNO in Severe Eosinophilic Asthma: The Role of CRSwNP. [PDF]

J Asthma Allergy
Garcia-Rivero JL, Abascal-Bolado B, Aranda Sobrino N, Ghadban Garrido C.   +3 more
europepmc   +1 more source

Eosinophilic Asthma

, 2019
Bushra Mubarak, Huma Shakoor, Fozia Masood   +2 more
openaire   +2 more sources

A novel JAK1 variant in chronic eosinophilic leukaemia with response to benralizumab

British Journal of Haematology, EarlyView.
Isabel C. Vallecillo‐Viejo, Michael D. Claiborne, Charles F. Anderson, Samantha Shafer, Alan Saven, Bryce A. Seifert, Morgan Similuk, Magdalena Walkiewicz, Irina Maric, Pia R. Crespo, Lori Broderick, Andrew A. White, Amy D. Klion   +12 more
wiley   +1 more source

Analysis of Selected Serum Cytokines to Evaluate the Early Efficacy of Benralizumab, Dupilumab, and Mepolizumab in Severe Eosinophilic Asthma Treatment. [PDF]

Int J Mol Sci
Niemiec-Górska A, Labus Ł, Mielcarska S, Glück J, Czuba Z, Cyrnek M, Branicka O, Rymarczyk B, Gawlik R.   +8 more
europepmc   +1 more source

Cytokine and Metabolomic Signatures of Mepolizumab Response Across Upper and Lower Airway Compartments in Severe Eosinophilic Asthma: An Exploratory Analysis. [PDF]

Pharmaceuticals (Basel)
Maniscalco M, Ambrosino P, Candia C, Di Stefano A, Gnemmi I, Zappa M, Ambrosino N, Visca D, Motta A.   +8 more
europepmc   +1 more source

Eosinophils in Asthma

Tuberculosis and Respiratory Diseases, 1999
openaire   +1 more source

Relationship Between Bronchodilator Reversibility and Spirometry Response to Dupilumab in Type 2 High Uncontrolled Severe Asthma

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 253-255, March 2025.
Robert Greig, Kirsten Stewart, Chris RuiWen Kuo, Rory Chan, Brian Lipworth   +4 more
wiley   +1 more source

A Real‐World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma

Clinical &Experimental Allergy, EarlyView.
Among patients with severe eosinophilic asthma, benralizumab was associated with greater improvements in asthma outcomes—such as improved asthma control, quality of life and remission rates—compared to biologic‐naïve patients. ABSTRACT Background Real‐world data on benralizumab in patients with severe eosinophilic asthma–while controlling for ...
Dennis Thomas, Vanessa M. McDonald, Gijo Thomas, Joy Lee, Li Ping Chung, Matthew Peters, Shakti D. Shukla, Yuto Hamada, Erin S. Harvey, Michael Fricker, Hayley See, Rejoy Sabin Thomas, Claude S. Farah, Andrew Gillman, Constance H. Katelaris, Gregory P. Katsoulotos, David Langton, Peter G. Middleton, Paul Reynolds, Janet Rimmer, Francis Thien, Stephen Vincent, John W. Upham, Peter G. Gibson   +23 more
wiley   +1 more source